GI Cancer Updates—2017 Oncology Annual Meeting
prIME Downloadable Slides
prIME Downloadable Slides

GI Cancer Updates—2017 Oncology Annual Meeting

Not a member of My prIME? Join now for instant access.

prIME Downloadable Slides in Gastrointestinal Cancer From the 2017 Oncology Annual Meeting in Chicago

Downloadable Slides

Downloadable Slides

CME

CME

0.75 AMA PRA Category 1 Credit

Release Date

Release Date

Jun 15, 2017

Expiration Date

Jun 15, 2018

Featured Expert

  • Thierry André, MD, Hopital Saint Antoine, Paris, France

Featured Topic

Abstract #3531: Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study

Featured Expert

  • Axel Grothey, MD, Mayo Clinic, Rochester, Minnesota, United States

Featured Topic

Abstract #3558: Response to pembrolizumab in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC)

Featured Expert

  • Charles S. Fuchs, MD, MPH, Yale Cancer Center, New Haven, Connecticut, United States

Featured Topic

Abstract #4003: KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer

Featured Expert

  • Yung-Jue Bang, MD, PhD, Seoul National University Hospital, Seoul, Korea

Featured Topic

Abstract #4012: KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer

This activity is specifically designed to meet the needs of medical, surgical, and radiation oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with cancer.

After successful completion of this educational activity, participants should be able to:

  • Evaluate best practices regarding the treatment of patients with cancer, including integration of novel therapeutic approaches and individualization of care

This educational activity is supported by a grant from Merck and Co., Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

GI Cancer Updates—2017 Oncology Annual Meeting - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 100%.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Dr André has disclosed that he has received consulting fees from Bristol-Myers Squibb. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Bang has disclosed that he has received consulting fees from MSD. He has also performed contracted research for MSD through his institution. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Fuchs has disclosed that he has received consulting fees from Agios, Bayer, Dicerna, Eli Lilly, Entrinsic Health, Five Prime Therapeutics, Genentech, Gilead Sciences, Kew, Merck, Merrimack, Sanofi, and Taiho. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Grothey has disclosed that he has received consulting fees from Bayer, Boehringer Ingelheim, Boston Biomedicals, Eli-Lilly, Genentech, and Taiho. He also disclosed performing contracted research for Bayer, Boston Biomedicals, and Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Elizabeth Cameron, PhD (clinical content planner/reviewer) – no relevant financial relationships
  • Christi Gray (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.